GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

GLP-1 (7-36) amide

Company
Johns Hopkins University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for GLP-1 (7-36) amide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07625202

    Creatine Supplementation During GLP-1a Therapy

    Not yet reported University of Saskatchewan 40 participants Est. completion 2027-12-31 1 site
    Other conditions: Sarcopenia
    View official trial listing →
  • Completed NCT NCT00393445

    Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans

    Not yet reported Ludwig-Maximilians - University of Munich 6 participants Est. completion 2007-05 1 site
    Other conditions: Hyperglycemia
    View official trial listing →
  • Completed NCT NCT00882492

    GLP 1 for Intraoperative Glycemic Control

    Not yet reported University of Pennsylvania 80 participants Est. completion 2011-05 1 site
    Other conditions: Hyperglycemia, Hypoglycemia
    View official trial listing →
  • Terminated NCT NCT00966654

    Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery

    Not yet reported Johns Hopkins University 12 participants Est. completion 2012-09 1 site
    Other conditions: CABG
    View official trial listing →
  • Completed NCT NCT01333163

    GLP-1: Acute Effects on Kidney Function in Healthy Men

    Not yet reported Jeppe Skov 12 participants Est. completion 2011-12 1 site
    Other conditions: Kidney Functional
    View official trial listing →
  • Status unknown NCT NCT02127996

    GLP-1 Loading During Elective Percutaneous Coronary Intervention

    Not yet reported Papworth Hospital NHS Foundation Trust 193 participants Est. completion 2021-07 1 site Stand-alone
    Cardiovascular disease Other conditions: Angina Pectoris, Reperfusion Injury, Coronary Heart Disease
    View official trial listing →
  • Completed NCT NCT02128022

    Cardioprotective Effects of GLP-1 and Their Mechanisms

    Not yet reported Papworth Hospital NHS Foundation Trust 32 participants Est. completion 2016-03 1 site Stand-alone
    Other conditions: Angina Pectoris
    View official trial listing →
  • Completed NCT NCT02591849

    GLP-1 Effects on Insulin and Glucagon in PTDM

    Not yet reported Oslo University Hospital 24 participants Est. completion 2015-03 1 site
    Other conditions: Post-transplant Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03502083

    Human Vasodilatory Effect of GLP-1

    Not yet reported Papworth Hospital NHS Foundation Trust 11 participants Est. completion 2017-03-01
    Type 2 diabetes Other conditions: Coronary Stenosis, Angina, Stable
    View official trial listing →
  • Completed NCT NCT04200625

    Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

    University of Miami 80 participants Est. completion 2019-12-09 1 site
    Other conditions: Epicardial Fat
    View official trial listing →
  • Completed NCT NCT04779697

    GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

    Not yet reported Yale University 96 participants Est. completion 2024-11-19 1 site
    Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT05751720

    Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

    Not yet reported, Not yet reported Dr Adnan Agha 30 participants Est. completion 2025-02 1 site
    Type 2 diabetes Other conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Liver Fat
    View official trial listing →
  • Not yet recruiting NCT NCT06682351

    Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

    Not yet reported Stanford University 200 participants Est. completion 2027-12 1 site
    Type 2 diabetesPrediabetes
    View official trial listing →
  • Enrolling by invitation NCT NCT07687589

    The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals

    Not yet reported University of Copenhagen 14 participants Est. completion 2027-04-28 1 site
    Other conditions: Emesis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.